Figure S1. Funnel plot for association studies of the CYP4F2 polymorphism on coumarin dose requirements.



Figure S2a Forest plot for the difference in logarithm of stable coumarin dose* for subjects with *CYP4F2* polymorphism (CT) compared to subjects with *CYP4F2* wild-type (CC)



Figure S2b. Forest plot for the difference in logarithm of stable coumarin dose* for subjects with *CYP4F2* polymorphism (TT) compared to subjects with *CYP4F2* wild-type (CC)



CI=Confidence Intervals; ES=Estimate
* exp(ES) gives the relative percentage difference as weekly dose in mg

Figure S3. Forest plot for the difference in logarithm of stable coumarin dose* for subjects with *CYP4F2* polymorphism (CT+TT) compared to subjects with *CYP4F2* wild-type (CC), according to dominant model and stratified by (A) ethnicity; (B) drug; (C) sex.

A) Asians



A) Blacks



A) Whites



A) Others



B) Acenocoumarol



B) Warfarin



c) Males


First Author
PY
ES (95% CI)
Aquilante CL 2006 0.10 (0.03, 0.17)
Borgiani P 2009 0.21 (-0.09, 0.50)
Borobia AM,Tong HY 2012-2016 -0.04 (-0.24, 0.16)
Botton MR 2011 0.07 (-0.03, 0.17)
Bourgeois S 2016 0.01 (-0.10, 0.12)
Caldwell MD 2008 0.17 (0.10, 0.25)
Cavallari LH 2010 -0.12 (-0.39, 0.15)
Cen HJ 2010 0.12 (0.05, 0.20)
Cerezo-Manchado JJ (a) 2013 0.12 (0.06, 0.18)
Cerezo-Manchado JJ (b) 2013 0.10 (0.07, 0.13)
Cha PC 2010 0.07 (-0.00, 0.14)
Gong IY 2011 0.01 (-0.06, 0.08)
Hirai K 2015 0.07 (-0.04, 0.18)
Isaza C 2010 -0.09 (-0.28, 0.10)
Jimenéz-Varo E 2015 0.11 (-0.03, 0.26)
Kringen MK 2011 -0.01 (-0.12, 0.09)
Lee KE, Kim HO 2012 -0.03 (-0.19, 0.12)
Lee MT 2009 -0.01 (-0.13, 0.12)
Lubitz SA 2010 0.04 (-0.13, 0.21)
Mazzaccarra C 2013 -0.02 (-0.14, 0.11)
Ozer M 2013 0.06 (-0.12, 0.25)
Pathare A 2012 0.06 (-0.13, 0.26)
Pautas E 2010 0.08 (-0.16, 0.33)
Pavani A 2012 0.03 (-0.13, 0.18)
Pérez-Andreu V 2009 0.18 (0.04, 0.31)
Perini JA 2010 0.04 (-0.05, 0.13)
Ramirez AH 2012 0.08 (0.03, 0.14)
Rathore SS 2012 0.03 (-0.10, 0.17)
Sagreiya H 2010 0.10 (-0.06, 0.26)
Shain MH 2011 -0.04 (-0.24, 0.16)
Shendre A 2016 0.08 (0.02, 0.14)
Suriapranata IM 2011 0.10 (-0.22, 0.41)
Tan SL 2013 0.13 (0.02, 0.23)
Tatarunas V 2014 -0.02 (-0.15, 0.10)
van Schie RM (a) 2013 0.06 (-0.00, 0.13)
van Schie RM (b) 2013 0.05 (-0.02, 0.13)
Wells PS 2010 0.05 (-0.09, 0.18)
Zambon CF 2011 0.08 (-0.00, 0.16)
Zhang JE 2009 0.14 (0.00, 0.28)
Overall (I-squared = 15.8%, p = 0.199) 0.07 (0.06, 0.09)
-.5
0
.5

c) Females



CI=Confidence Intervals; ES=Estimate
* exp(ES) gives the relative percentage difference as weekly dose in mg

Figure S4. Forest plot for the difference in logarithm of stable coumarin dose* for subjects with *CYP4F2* polymorphism (CT+TT) compared to subjects with *CYP4F2* wild-type (CC), according to dominant model and stratified by (A) CYP2C9; (B) *VKORC1*.

CYP2C9*2 or *3



CYP2C9 wild type



VKORC1 rs9923231 GG (Wild type)



VKORC1 rs9923231 GA or AA (mutated)



CI=Confidence Intervals; ES=Estimate
* exp(ES) gives the relative percentage difference as weekly dose in mg